Kiadis and Celmed Merge to Create New Force in Oncology

30-Nov-2006

Kiadis B.V. and Celmed BioSciences announced their plans to merge both oncology-focused companies. The combined company will be named Kiadis Pharma B.V. and headquartered in the Netherlands with facilities in the Netherlands and Canada.

According to the company, Kiadis Pharma is fully dedicated to in-house pharmaceutical product development and has extensive experience in oncology. Kiadis Pharma currently has a small molecule pipeline with four products in various phases of clinical development allowing fast track potential and significant market opportunities. Its lead product, ATIR, has successfully allowed blood cancer patients, without access to a fully matched donor, to receive a life-saving transplantation of bone-marrow. ATIR is currently in phase I/II clinical development and could open treatment opportunities for a significant group of patients.

The combination of Kiadis and Celmed BioSciences shall create a leading international biotechnology company with proven strengths in oncology, both in products and development platforms.

The new management team of Kiadis Pharma will be headed by Manja Bouman as CEO and includes executives from both companies. The cross-Atlantic management team is well positioned to drive strategic growth and to ensure the company remains on track to realize its market potential. The team is firmly embedded in the relevant clinical communities with excellent links to regulators, and expertise in the entire product development value chain. Kiadis Pharma will incorporate strong external validation through the planned establishment of renowned scientific and clinical advisory boards as well as the backing of knowledgeable shareholders.

The merger is still subject to approval by the shareholders of both companies as well as regulatory approvals and customary closing conditions. Financial details of the upcoming transaction are not disclosed.

https://www.bionity.com/en/news/59813/kiadis-and-celmed-merge-to-create-new-force-in-oncology.html